scholarly journals Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

2014 ◽  
Vol 168 (1) ◽  
pp. 69-81 ◽  
Author(s):  
Tim H. Brümmendorf ◽  
Jorge E. Cortes ◽  
Cármino Antonio Souza ◽  
Francois Guilhot ◽  
Ladan Duvillié ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed

scholarly journals Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

2020 ◽  
Vol 189 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Young Rok Do ◽  
Jae‐Yong Kwak ◽  
Jeong A. Kim ◽  
Hyeoung Joon Kim ◽  
Joo Seop Chung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Term Data

scholarly journals Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

2017 ◽  
Vol 179 (2) ◽  
pp. 219-228 ◽  
Author(s):  
Timothy P. Hughes ◽  
Eduardo Munhoz ◽  
Marco Aurelio Salvino ◽  
Tee Chuan Ong ◽  
Alaa Elhaddad ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Dose Optimization ◽  
Newly Diagnosed

scholarly journals Acquired Melanonychia and Mucocutaneous Hyper pigmentation with Hydroxyurea Therapy for the Treatment of Blast Crisis of Chronic Myeloid Leukaemia: A Case Report

2019 ◽  
Vol 7 (2) ◽  
pp. 106-108
Author(s):  
Md Atiquzzaman ◽  
Md Abu Taher ◽  
PK Bhattacharyya ◽  
Momtaz Begum ◽  
Tayef Md Tahlil Islam ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Blast Crisis ◽  
Correct Diagnosis ◽  
Antineoplastic Agent ◽  
Chronic Phase ◽  
The Body ◽  
Close Monitoring ◽  
Hydroxyurea Therapy

Hydroxyurea is an antineoplastic agent used to treat chronic myeloid leukaemia (especially in accelerated phaseand blast crisis). We report this unique case of a 60 year old lady who was diagnosed case of chronic-phase ofchronic myeloid leukaemia was getting imatinib and well suited. As a consequence of imatinib noncompliance,she developed blast crisis and was subsequently hydroxyurea initiated. At her 3rdmonth follow-up she presentedwith blackening of her exposed parts of the body, all three mucocutaneous areas especially skin of her hands, feet,fingernails, toenails and oral mucosa in some extent.Hydroxyurea-induced melanonychia and mucocutaneous hyperpigmentation is rarely reported. To the best of ourknowledge, this is one of the few published reports of hydroxyurea induced mucocutaneous hyperpigmentationand melanonychia involving all 20 nails. The mainstays of treatment are withdrawal of the drug andsun-avoidance; laser therapy is a hope for cure in small percentage of permanent cases. A correct diagnosis isessential to prevent undue fears in the patient. Proper advice to the patient regarding adverse reactions ofparticular agent and close monitoring after prescribing should be ensured to prevent harm to patients. Alwaysshould remember, drugs not only save life, but can even take it. Bangladesh Crit Care J September 2019; 7(2): 106-108

scholarly journals The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians

2017 ◽  
Vol 13 (01) ◽  
pp. 15
Author(s):  
Ahmet Emre Eskazan ◽  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukaemia ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Subsequent Paper ◽  
Refractory Disease ◽  
Newly Diagnosed

Although the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newly-diagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1102-1102 ◽  
Author(s):  
Davi D M Ross ◽  
Andrew Grigg ◽  
Anthony Schwarer ◽  
Christopher Arthur ◽  
Kerryn Loftus ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Median Duration ◽  
Genomic Dna ◽  
Chronic Phase ◽  
Patient Specific ◽  
Molecular Response ◽  
Imatinib Treatment ◽  
Complete Molecular Response

Abstract After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict sensitivity criteria (‘complete molecular response’, CMR). Many patients who stop imatinib in CMR will relapse, but small numbers have been reported with sustained CMR after imatinib withdrawal. We designed a non-randomised prospective Phase 2 study of imatinib withdrawal in adult chronic phase CML patients in CMR for ≥2 years (ACTRN012606000118505). Patients were treated in multiple centres around Australia, and RQ-PCR for BCR-ABL was performed centrally: monthly for the first year after imatinib withdrawal, and 2-monthly in the second year. Molecular relapse was defined as a single PCR result above the level of major molecular response (MMR) or any two consecutive positive results. Molecular relapse was treated with imatinib and patients were monitored monthly for 12 months to assess response to retreatment. Patients were enrolled in two cohorts: imatinib de novo (IM only, n=5) and imatinib after prior interferon therapy (IFN-IM, n=13). The median duration of prior IFN was 39 months. Both cohorts continue to accrue. For all 18 patients the median age at study entry was 58 years; 44% were male. The median duration of imatinib treatment was 60 months (R40-89). The Kaplan-Meier estimate of the rate of sustained CMR after 12 months off treatment was 67% (95% confidence interval 40–85%, see Figure). Ten of 13 IFN-IM patients (77%) remain in CMR, and 7 of these have been in CMR for at least 12 months without treatment (maximum 23 months). The median follow-up in the IM only patients is currently only 7 months (R1-15), and 3/5 remain in CMR. All molecular relapses in both groups have occurred within 5 months of stopping imatinib. The median duration of prior imatinib treatment was not different in the 5 patients with loss of CMR (76 months) versus those in stable CMR (60 months; p=0.59). Among the 5 patients with loss of CMR the median time to molecular relapse was 3 months (range 2–5 months). Two relapsing patients lost MMR, and 3 had detectable BCR-ABL mRNA below this level. No patient has experienced haematological relapse or developed a kinase domain mutation. At last follow-up all 5 relapsing patients had regained CMR after a median of 5 months of re-treatment with imatinib. Patient-specific DNA Q-PCR assays were developed to test whether minimal residual disease (MRD) was detectable in genomic DNA in patients in CMR defined by RQ-PCR for BCR-ABL mRNA. Results are available for 6 patients, 3 of whom have relapsed. One relapsing patient had BCR-ABL DNA detected prior to imatinib withdrawal. In the remaining 2 relapsing patients BCR-ABL DNA was detected after imatinib withdrawal, but 2–3 months prior to the detection of BCR-ABL mRNA by RQ-PCR. BCR-ABL DNA increased by at least 1-log between the time of the first positive result and the detection of molecular relapse by RQ-PCR. The 3 patients in stable CMR had no detectable BCR-ABL DNA. In conclusion, with close molecular monitoring imatinib withdrawal in stable CMR appears to be safe: currently all patients are either in stable CMR off treatment or back in CMR after re-treatment. Withdrawal of effective treatment outside the setting of a clinical trial is not recommended. Monitoring of MRD by genomic DNA Q-PCR was able to detect molecular relapse prior to mRNA RQ-PCR, and shows promise for the prospective identification of patients at high risk of relapse. There is an apparent dichotomy of response between early molecular relapse and durable CMR, at least in patients treated with imatinib after IFN. It is too early to identify clinical or laboratory factors (such as prior IFN treatment) that may influence the probability of sustained CMR without treatment. Figure Figure

Sign in / Sign up

Export Citation Format

Share Document